Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease

被引：0

作者：

Colin Green

Joanna Picot

Emma Loveman

Andrea Takeda

Jo Kirby

Andrew Clegg

机构：

[1] University of Southampton,Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development

来源：

PharmacoEconomics | 2005年 / 23卷

关键词：

Memantine; Cholinesterase Inhibitor; Rivastigmine; Galantamine; Personal Social Service;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer’s disease. Patients had a mean age of 74 years, a mean disease duration of 1 year and a mean Alzheimer’s disease assessment scale-cognitive subscale score of 24.

引用

页码：1271 / 1282

页数：11

共 50 条

[1] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease
Bosanquet, N
Yeates, A
PHARMACOECONOMICS, 2006, 24 (06) : 623 - 625
[2] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease
Green, C
Picot, J
Loveman, E
Takeda, A
Kirby, J
Clegg, A
PHARMACOECONOMICS, 2005, 23 (12) : 1271 - 1282
[3] Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease
Nick Bosanquet
Andrew Yeates
PharmacoEconomics, 2006, 24 : 623 - 625
[4] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease - The authors' reply
Green, C
Picot, J
Loveman, E
Takeda, A
Kirby, J
Clegg, A
PHARMACOECONOMICS, 2006, 24 (06) : 625 - 626
[5] Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea
Suh, Guk-Hee
VALUE IN HEALTH, 2009, 12 : S49 - S54
[6] Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain
Antonanzas, F
Badenas, J
François, C
Guilhaume, C
VALUE IN HEALTH, 2003, 6 (06) : 765 - 765
[7] Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland
François, C
Sintonen, H
Sulkava, R
Rive, B
CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 373 - 384
[8] Cholinesterase inhibitors in Alzheimer's disease - Are they worth the cost?
Whitehouse, PJ
CNS DRUGS, 1999, 11 (03) : 167 - 173
[9] Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease - A review with methodological considerations
Wimo, A
DRUGS & AGING, 2004, 21 (05) : 279 - 295
[10] Treatment of Alzheimer's disease with cholinesterase inhibitors in Germany: A cost-effectiveness study
Faltraco, F
Happich, M
Reisig, V
Teipel, SJ
Moeller, HJ
Hampel, H
NEUROBIOLOGY OF AGING, 2004, 25 : S336 - S336

← 1 2 3 4 5 →